Humacyte adds Scott Coward and Paul Kuznik to its board, bolstering the company's commercialization and global operations capabilities as it continues to develop its bioengineered human tissue platform.
Appointment of two life science industry veterans to the board adds commercialization expertise but does not change financial outlook.
Humacyte, Inc. has expanded its board of directors with the appointment of industry veterans Scott Coward and Paul Kuznik. The new directors bring extensive expertise in global commercialization and enterprise leadership to the biotechnology firm as it scales its bioengineered tissue platform.
The new board members are Scott Coward and Paul Kuznik, both of whom are life science industry veterans with experience in commercialization and global operations.